Urinalysis X X See Section 9.4.4. Pregnancy Test (WOCBP) X XSerum/urine pregnancy test must be perform ed (urine pregnancy test: minimum sensitivity 25 IU/L or equivalent units of hCG) within 24 hours prior to administration of study treatment. Revised Protocol No.: 04 Date: 31-May-2019 33 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-4: Additional Treatment Procedural Outline (CA021002) ProcedureAdditional Cycles EOTa,b,cNotes D1 If the pregnancy test is positive, hold all stu dy treatments and perform confirmatory testing. If pregnancy is confir med, permanently discontinue all study treatment and immediately notify BMS Medical Monitor/Study Director or designee (see Section 9.2.5 ). AE Reporting and Concomitant Medication Assessments Clinical Complaints XTo be completed within 2 weeks of Day 0 o nly if participant entered survival follow up. Concomitant Medication AssessmentsX Review prior to dosing. Monitor for Non-serious AEsXNon-serious AEs will be collected starting with the first dose of study medication and through 100 days after last dose of study drug. Monitor for SAEs X See note in Table 2-1 . Efficacy Assessments Body ImagingEvery 8 weeks ( ±1 week) prior to dosing at C3 and C5X See Section 9.1 . Brain ImagingFor participants with history of brain metastases, surveillance scans to be done per standard of care frequency, or sooner if clinically indicated.See Section 9.1. Bone Scan As clinically indicated.